乳腺癌免疫治疗的现状及展望  

Immunotherapy of breast cancer: current status and prospects

作　　者：洪进[1] 陈小松[1] 沈坤炜[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院乳腺疾病诊治中心,上海200025

出　　处：《肿瘤》2013年第12期1125-1129,共5页Tumor

摘　　要：乳腺癌的免疫治疗是继手术、化疗、放疗、内分泌治疗和靶向治疗之后,一种能潜在提高乳腺癌患者预后的治疗方案。免疫治疗的策略包括增强树突状细胞和效应T细胞等细胞及分子的抗肿瘤免疫反应,抑制调节性T细胞和髓源抑制细胞等在肿瘤微环境中的促肿瘤免疫抑制反应,从而起到抗肿瘤的效果。目前,单克隆抗体形式的被动性免疫治疗已经可以明显提高人类表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)阳性乳腺癌患者的生存率;同时,乳腺癌相关疫苗的研究也已取得了较大的突破,而T细胞过继性免疫治疗以及调节T细胞功能的单克隆抗体等研究也已经在开展。本文对乳腺癌免疫治疗的现状和展望作一述评。Immunotherapy is a new potential approach to improve the prognosis of breast cancer, on the basis of surgery, chemotherapy, radiation therapy, endocrine therapy and targeted therapy. The strategies of immunotherapy include enhancing cellular and molecular anti-tumor immune responses, such as boosting the activations of dendritic cells and cytotoxic T cells, and reducing immunosuppression in the tumor microenvironment, for instance, inhibiting the function of regulatory T cells and myeloid derived suppressor cells. To date, passive immunotherapy, in the form of monoclonal antibodies, has significantly improved the survival of patients with human epidermal growth factor receptor-2 （HER-2）- positive breast cancer. At the same time, a great breakthrough has been achieved in studies of breast cancer-related vaccines. Besides, the studies on adoptive T cells immunotherapy and antibodies to modulate T cell function are under development. This review is to present the current information and prospects of immunotherapy of breast cancer.

关 键 词：乳腺肿瘤 免疫疗法 癌症疫苗 抗体 单克隆 抗原呈递细胞 

分 类 号：R737.9[医药卫生—肿瘤]